The Timeless Necessity of GLIMEPIRIDE in Diabetes Management
The Amaryl Compendium is a concise repository of over 20 years of clinical data, research, and real-world evidence on Amaryl (glimepiride). Designed as a knowledge resource, it brings together key studies, safety, and efficacy insights to support informed diabetes care. Reflecting Amaryl’s long-standing legacy, the Compendium serves as a trusted guide for evidence-based treatment decisions.
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
